See the DrugPatentWatch profile for Cotempla
What is Cotempla XR?
Cotempla XR is an extended-release formulation of methylphenidate used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adults [1]. It is a central nervous system stimulant that works by affecting the balance of certain natural substances in the brain [2]. The "XR" in its name signifies its extended-release mechanism, designed to provide symptom control throughout the day [1].
How does Cotempla XR work?
Cotempla XR contains methylphenidate, which is believed to block the reuptake of dopamine and norepinephrine in the brain. By increasing the levels of these neurotransmitters in the synaptic cleft, it enhances neurotransmission, particularly in the prefrontal cortex, which is thought to be involved in regulating attention and impulse control [2]. This mechanism helps to manage the symptoms associated with ADHD.
When can I expect Cotempla XR to be available?
The availability of specific drug formulations can be influenced by various factors, including manufacturing schedules and regulatory approvals. For detailed information on the current availability or expected timelines for Cotempla XR, consulting drug databases or pharmaceutical news sources may be helpful.
What is the difference between Cotempla XR and other methylphenidate products?
Cotempla XR is an extended-release formulation, meaning it is designed to release medication gradually over time. This differs from immediate-release formulations of methylphenidate, which release the entire dose at once and require more frequent administration. The extended-release mechanism of Cotempla XR aims to provide consistent symptom management for a longer duration, potentially reducing the need for midday doses. Other methylphenidate products may vary in their release mechanisms, active ingredients, or dosage forms [1, 2].
Are there any patent expirations for Cotempla XR?
Information regarding patent expiry dates for specific drug formulations like Cotempla XR is crucial for understanding market exclusivity and the potential for generic competition. DrugPatentWatch.com tracks patent information for pharmaceuticals. For the most up-to-date and detailed patent status of Cotempla XR, DrugPatentWatch.com can be a valuable resource [3].
What are the potential side effects of Cotempla XR?
Common side effects associated with methylphenidate products, including Cotempla XR, can include decreased appetite, difficulty sleeping, headache, stomach pain, and weight loss [2]. More serious side effects, though less common, can include cardiovascular issues, psychiatric symptoms, and circulation problems in the fingers and toes. Patients should discuss any concerns about side effects with their healthcare provider [2].
Who manufactures Cotempla XR?
Cotempla XR was developed and is marketed by Takeda Pharmaceuticals [1].
---
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com